drugset / Trial / NCT05962021
Neoadjuvant Toripalimab for Non-squamous NSCLC With EGFR Mutation
Phase 2
Unknown
126 enrolled
Peking University People's Hospital
Shanghai Junshi Bioscience Co., Ltd. · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study was designed to investigate the efficacy and safety of neoadjuvant Toripalimab (anti-PD1) plus chemotherapy for patients with resectable II-IIIB non-squamous NSCLC harboring EGFR mutation, and to explore the potential predictive and prognostic biomarkers, aiming to provide more abundant evidences for the preoperative treatment decision of non-squamous NSCLC patients.
Timeline
- Start
- 2023-08-01
- Primary completion
- 2026-06-30
- Completion
- 2026-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Albumin-Bound Paclitaxel | Unknown | 260 mg/m2 | — |
| Subject | Carboplatin | Small molecule | — | — |
| Subject | Pemetrexed | Small molecule | 500 mg/m2 | — |
| Subject | Toripalimab | Monoclonal antibody | 240 mg | — |